

Title (en)
ANTI-JAGGED 1/JAGGED 2 CROSS-REACTIVE ANTIBODIES, ACTIVATABLE ANTI-JAGGED ANTIBODIES AND METHODS OF USE THEREOF

Title (de)
ANTI-JAGGED-1/JAGGED-2-KREUZREAKTIVE ANTIKÖRPER, AKTIVIERBARE ANTI-JAGGED-ANTI-KÖRPER UND ANWENDUNGSVERFAHREN DAFÜR

Title (fr)
ANTICORPS À RÉACTION CROISÉE ANTI-JAGGED 1/JAGGED 2, ANTICORPS ANTI-JAGGED ACTIVABLES ET LEURS PROCÉDÉS D'UTILISATION

Publication
EP 2863948 B1 20181024 (EN)

Application
EP 13807400 A 20130621

Priority
• US 201261663307 P 20120622
• US 201361749212 P 20130104
• US 201361749486 P 20130107
• US 201361755810 P 20130123
• US 2013047109 W 20130621

Abstract (en)
[origin: WO2013192550A2] This invention relates generally to the generation of antibodies, e.g., monoclonal antibodies including fully human monoclonal antibodies, that recognize Jagged 1 and/or Jagged 2, to antibodies, e.g., monoclonal antibodies including fully human antibodies that recognize Jagged 1 and/or Jagged 2, and nucleic acid molecules that encode antibodies, e.g., nucleic acid molecules that encode monoclonal antibodies including fully human cross-reactive antibodies that recognize both Jagged 1 and Jagged 2, and to methods of making the anti- Jagged antibodies and methods of using the anti- Jagged antibodies as therapeutics, prophylactics, and diagnostics. The invention also relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically bind to Jagged 1 and Jagged 2, and to methods of making and using these activatable anti- Jagged antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

IPC 8 full level
A61K 39/395 (2006.01); **A61K 47/66** (2017.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07K 7/00** (2006.01); **C07K 16/28** (2006.01)

CPC (source: EP KR US)
A61K 39/39558 (2013.01 - EP US); **A61K 47/68031** (2023.08 - EP KR US); **A61K 47/6811** (2017.08 - EP KR US); **A61K 47/6851** (2017.08 - EP KR US); **A61K 49/0058** (2013.01 - KR US); **A61P 9/00** (2018.01 - EP); **A61P 11/00** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **C07K 16/18** (2013.01 - US); **C07K 16/28** (2013.01 - EP US); **C07K 16/2887** (2013.01 - US); **C07K 16/2896** (2013.01 - EP KR US); **G01N 33/6893** (2013.01 - KR); **A61K 2039/505** (2013.01 - EP KR US); **C07K 2317/21** (2013.01 - EP KR US); **C07K 2317/33** (2013.01 - EP KR US); **C07K 2317/52** (2013.01 - EP KR US); **C07K 2317/54** (2013.01 - KR US); **C07K 2317/55** (2013.01 - EP KR US); **C07K 2317/56** (2013.01 - KR US); **C07K 2317/565** (2013.01 - KR US); **C07K 2317/569** (2013.01 - KR US); **C07K 2317/622** (2013.01 - EP KR US); **C07K 2317/73** (2013.01 - EP KR US); **C07K 2317/76** (2013.01 - KR US); **C07K 2317/92** (2013.01 - EP KR US); **C07K 2317/94** (2013.01 - KR US); **C07K 2319/00** (2013.01 - EP KR US); **C07K 2319/30** (2013.01 - KR US); **C07K 2319/50** (2013.01 - EP KR US); **G01N 2333/70596** (2013.01 - KR)

C-Set (source: EP US)
A61K 39/39558 + A61K 2300/00

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2013192550 A2 20131227; WO 2013192550 A3 20140424; AU 2013278075 A1 20150122; AU 2013278075 B2 20180517; BR 112014031689 A2 20170725; CA 2876904 A1 20131227; CA 2876904 C 20191203; CN 104661677 A 20150527; CO 7151488 A2 20141229; EP 2863948 A2 20150429; EP 2863948 A4 20160309; EP 2863948 B1 20181024; HK 1204576 A1 20151127; IL 236348 A0 20150226; IN 2635MUN2014 A 20151016; JP 2015521625 A 20150730; KR 20150037857 A 20150408; MX 2014016038 A 20150814; PE 20150643 A1 20150529; PH 12015500125 A1 20150316; RU 2015101803 A 20160820; SG 11201408554Q A 20150227; US 10301380 B2 20190528; US 2014010810 A1 20140109; US 2016200826 A1 20160714; US 2017298125 A1 20171019; US 2019367589 A1 20191205; US 9127053 B2 20150908; US 9688748 B2 20170627

DOCDB simple family (application)
US 2013047109 W 20130621; AU 2013278075 A 20130621; BR 112014031689 A 20130621; CA 2876904 A 20130621; CN 201380043521 A 20130621; CO 14280541 A 20141222; EP 13807400 A 20130621; HK 15105219 A 20150601; IL 23634814 A 20141218; IN 2635MUN2014 A 20141226; JP 2015518613 A 20130621; KR 20157001567 A 20130621; MX 2014016038 A 20130621; PE 2014002517 A 20130621; PH 12015500125 A 20150121; RU 2015101803 A 20130621; SG 11201408554Q A 20130621; US 201313923935 A 20130621; US 201514815167 A 20150731; US 201715631116 A 20170623; US 201916376252 A 20190405